Clinical Scorecard: Avoiding Radiation in Uveal Melanoma
At a Glance
| Category | Detail |
|---|---|
| Condition | Uveal Melanoma |
| Key Mechanisms | Ablation therapy and anti-VEGF injections |
| Target Population | Patients with small uveal melanoma |
| Care Setting | Ocular oncology and retina clinics |
Key Highlights
- 105 patients treated with ablation therapy showed tumor control without radiation.
- Visual acuity improved from 20/63 to 20/32 over the study period.
- 85% of patients maintained vision better than 20/40.
- Tumor-associated maculopathy was responsive to anti-VEGF therapy.
- Average follow-up of 79 months demonstrated sustained outcomes.
Guideline-Based Recommendations
Diagnosis
- Gene expression profiling for tumor classification.
Management
- Use of ablation therapy and intravitreal bevacizumab injections.
Monitoring & Follow-up
- Regular assessment with spectral-domain optical coherence tomography (SD-OCT).
Risks
- Potential development of tumor-associated maculopathy.
Patient & Prescribing Data
Patients with small uveal melanoma treated without radiation.
Bevacizumab administered approximately 6 times per year with a treat-and-adjust approach.
Clinical Best Practices
- Avoid radiation therapy when possible to prevent radiation-associated complications.
- Monitor visual acuity and tumor status regularly post-treatment.
- Utilize anti-VEGF therapy for managing tumor-associated maculopathy.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.